Relacorilant 150 mg once daily (QD)

Phase 3

Corcept Therapeutics Incorporated (CORT)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

15 competitors in Ovarian Cancer

ZNTLazenosertib

GBIOGB-5267

AZNSaruparib (AZD5305)

Drug Information

Target Indication

Ovarian Cancer

Clinical Trial

NCT06906341

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMAPending

Lifyorli

Treatment of adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer

Orphan

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

CORT

Corcept Therapeutics Incorporated

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

RelacorilantPhase 3

Recurrent Ovarian Cancer

MifepristonePhase 3

Depressive Disorder, Major

mifepristone 600 mgPhase 3

Major Depressive Disorder

Nab-paclitaxel 100 mg/m^2Phase 3

Ovarian Neoplasm

CORT125134Phase 2

Cushing's Syndrome

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts